New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
06:41 EDTCTICCTI BioPharma upgraded to Buy from Hold at WallachBeth
WallachBeth upgraded CTI BioPharma to Buy with a $4.50 price target citing the recent pullback in shares. The firm believes the company's Pacritinib is a differentiated JAK2 kinase inhibitor from Jakafi with less thrombocytopenia.
News For CTIC From The Last 14 Days
Check below for free stories on CTIC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
09:10 EDTCTICOn The Fly: Pre-market Movers
Subscribe for More Information
05:31 EDTCTICCTI BioPharma to host conference call
Subscribe for More Information
05:18 EDTCTICCTI BioPharma, Servier enter exclusive PIXUVRI license, collaboration agreement
Subscribe for More Information
September 15, 2014
15:06 EDTCTICCTI BioPharma management to meet with Piper Jaffray
Group luncheon to be held in New York on September 16 hosted by Piper Jaffray.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use